WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results